Sponsor Overview
Explore verified public information about Beacon Therapeutics (Formerly AGTC)'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 0 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
No evidence found.
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria At Beacon Therapeutics, we are committed to developing products that bring new, innovative gene therapies, like laru-zova (AGTC-501) (laruparetigene zovaparvovec), to patients with serious diseases with no or limited treatment options. Currently, Beacon Therapeutics does not offer an expanded access program and is not accepting expanded access requests for our investigational products, including laru-zova (AGTC-501). We understand patient interest in accessing laru-zova (AGTC-501) outside of clinical trials and prior to regulatory approval. However, participation in one of our clinical trials is currently the most appropriate way to access our investigational products. Please search ClinicalTrials.gov and the Beacon Clinical Trials webpage for publicly available information related to Beacon Therapeutics’ ongoing clinical trials. If you have any questions about Beacon Therapeutics’ EA policy, please contact expandedaccess@beacontx.com .
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.